Caladrius stockholders approve merger with Cend Therapeutics, 1:15 reverse split, name change to Lisata Therapeutics

LISATA THERAPEUTICS, INC.

Merger with Cend approved: 25,973,235 for, 2,912,622 against, 172,676 abstain.
Reverse stock split at 1:15 ratio approved: 31,343,168 for, 7,665,240 against.
Name change to Lisata Therapeutics approved: 34,861,858 for, 4,003,401 against.
Merger close expected Sep 15, 2022; combined company to trade as LSTA on Nasdaq.
Board set reverse split ratio at 1:15; effective Sep 14, 2022 at 5:00 PM ET.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.